Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:

NCT ID: NCT05998447 Recruiting - Clinical trials for Biliary Tract Cancer

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Start date: September 18, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, multicenter, open-label study with a safety run-in to evaluate the safety and efficacy of GEN-001 in combination with pembrolizumab or in combination with pembrolizumab and mFOLFOX for patients with advanced refractory BTC who have progressed after 1 or 2 prior standard therapy and are not candidates for any other standard therapy. The safety run-in phase will be conducted before the main study phase

NCT ID: NCT05994001 Recruiting - Clinical trials for Biliary Tract Cancer

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In this clinical study, we will evaluate the efficacy and safety of cardonilimumab (PD1 monoclonal antibody and CTLA-4 monoclonal antibody bisspecific antibodies) and LM-302 (Claudin18.2-ADC) in Claudin18.2-positive advanced BTC patients who have progressed after SOC and PD1/PD-L1 monoclonal antibody treatment.

NCT ID: NCT05942807 Recruiting - Clinical trials for Biliary Tract Cancer

Observational Monocentric Study on Biliary Tract Cancer (BABEL)

BABEL
Start date: May 15, 2021
Phase:
Study type: Observational

BABEL is an observational, single-center, prospective study about patients affected by biliary tract cancers (BTC) treated at the Medical Oncology Unit of the FPUAG - IRCCS.

NCT ID: NCT05935579 Recruiting - Immunotherapy Clinical Trials

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Start date: December 14, 2022
Phase: Phase 2
Study type: Interventional

Explore the impact of the first-line application of Durvalumab combined with Lenvatinib, with or without chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers.

NCT ID: NCT05835778 Recruiting - Clinical trials for Biliary Tract Cancer

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Start date: June 7, 2023
Phase:
Study type: Observational

To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting.

NCT ID: NCT05823987 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

OPTIONS-05
Start date: May 16, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of oncolytic virotherapy combined with Tislelizumab plus lenvatinib in patients with advanced biliary tract cancer (BTC).

NCT ID: NCT05820906 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer

NCT ID: NCT05812430 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

NCT ID: NCT05781074 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)

CASTLE-08
Start date: March 23, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib in patients with Immune Checkpoint Inhibitor previously treated advanced biliary tract cancer (BTC).

NCT ID: NCT05775159 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.